Low-dose acyclovir reduces the reactivation of herpes simplex and varicella zoster viruses after allogeneic stem cell transplantation

HIGHLIGHTS

• What: The authors aimed to evaluate the impact of using a lower dose of oral acyclovir (400 mg twice daily) on the incidence of breakthrough of HSV and VZV reactivation in alloSCT recipients. The study showed 0% VZV reactivation, which is lower than the 5% VZV-only disease reported by Boeckh et_al during the first year post-transplant using oral acyclovir 800 mg twice daily .
• Who: Sorana G. Ursu et al. from the Division of Hematology and Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, USA have published the research work: Review began 11/26/2024 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.